These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

724 related items for PubMed ID: 17706711

  • 21. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS, Ryan CW, Jung LL.
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [Abstract] [Full Text] [Related]

  • 24. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT.
    J Urol; 2000 Jan; 163(1):181-6. PubMed ID: 10604342
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.
    Cancer; 2004 Mar 01; 100(5):892-9. PubMed ID: 14983482
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Prostate cancer and bone metastases: medical treatment.
    Clark PE, Torti FM.
    Clin Orthop Relat Res; 2003 Oct 01; (415 Suppl):S148-57. PubMed ID: 14600605
    [Abstract] [Full Text] [Related]

  • 29. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS, Pitts WR.
    J Urol; 2003 Nov 01; 170(5):1703-8. PubMed ID: 14532759
    [Abstract] [Full Text] [Related]

  • 30. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR.
    Urology; 2002 Sep 01; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.
    Bernat MM, Pasini J, Mareković Z.
    Coll Antropol; 2005 Dec 01; 29(2):589-91. PubMed ID: 16417166
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML.
    J Urol; 2008 May 01; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Preservation of bone health in prostate cancer.
    Lattouf JB, Saad F.
    Curr Opin Support Palliat Care; 2007 Oct 01; 1(3):192-7. PubMed ID: 18685362
    [Abstract] [Full Text] [Related]

  • 39. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM, Ma JZ, Basler JW, Welch MD.
    Urology; 2006 Jan 01; 67(1):152-5. PubMed ID: 16413352
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.